Compare ResMed Inc. (RMD) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Vertiv Holdings Co — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.73B), while Vertiv Holdings Co trades at $259.52 (market cap $101.21B). The key difference: Vertiv Holdings Co is far larger — about 3.2× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.2%). Which is the better fit depends on your goals.
| RMD | VRT | |
|---|---|---|
Market Cap | $31.73B | $101.21B |
Sector | Health | Technology |
52-Week High | $283.28 | $376.23 |
52-Week Low | $182.82 | $134.84 |
Enterprise Value | $31.08B | $101.44B |
Dividend Yield | 1.2% | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% on the day, with a bearish technical signal and key support at $218. The company reported strong Q4 2026 results, beating EPS estimates at $2.95, and maintains robust profitability with a 26.94% net income margin. Revenue growth remains solid, reaching $5.15B in 2025, though weak 2027 sales guidance has pressured the stock. A dividend of $0.66 is scheduled for payment in September 2026.
Outlook is mixed: strong fundamentals and a consensus price target of $235.70 suggest upside, but bearish technicals and investor lawsuits pose near-term risks. The stock offers value with a P/E of 21.19, yet competitive and regulatory challenges require monitoring for sustained growth.
Vertiv Holdings Co. (VRT) trades at $290.83, up 3.67% today, reflecting strong momentum. The stock exhibits a bullish technical trend, supported by robust fundamentals including consistent earnings beats and projected revenue growth from $10.23B in 2025 to $11.5B in 2026. Recent news highlights its strategic acquisition of UtilityInnovation Group for up to $2.6B, positioning it at the forefront of AI-driven data center infrastructure demand.
Outlook remains positive given Wall Street's strong buy consensus (95% buy ratings) and a $355.17 price target, implying 22% upside. Key risks include execution of acquisitions, high valuation multiples, and sensitivity to AI capex cycles. The stock presents a growth opportunity tied to data center expansion, but investors should weigh premium valuations against earnings delivery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
